Afatinib in patients with EGFR mutation-positive (EGFRm plus ) NSCLC harbouring uncommon mutations: Experience in 'Real-World' clinical practice

被引：0
|
作者：
Maerten, Angela [1 ]
Brueckl, Wolfgang [2 ]
Laack, Eckhart [3 ]
Hoffmann, Christopher [1 ]
Zhou, Caicun [4 ]
Wu, Yi-Long [5 ,6 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[2] Paracelsus Med Univ, Gen Hosp Nuernberg, Nurnberg, Germany
[3] Hamatoonkol Hamburg, Hamburg, Germany
[4] Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
[6] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
LUNG-CANCER;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
337
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [21] Real World Molecular Testing in Patients with EGFR Mutation-Positive (EGFRM plus ) Locally Advanced or Metastatic NSCLC in Routine Practice in Germany - Interim Results of The Clinical Registry Panorama
    Schuette, Wolfgang
    Schumann, Christian
    Buettner, Reinhard
    Deppertnann, Karl-Matthias
    Reinmuth, Niels
    Thomas, Michael
    Wroblewski, Mark
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 118 - 118
  • [22] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Lu, Shun
    Shih, Jin-Yuan
    Jang, Tae-Won
    Liam, Chong-Kin
    Yu, Yongfeng
    ADVANCES IN THERAPY, 2021, 38 (05) : 2038 - 2053
  • [23] Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres
    Tudor, R.
    Gibson, A.
    Hao, F.
    Dean, M.
    Kopciuk, K.
    Bebb, G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S839 - S840
  • [24] Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
    Shun Lu
    Jin-Yuan Shih
    Tae-Won Jang
    Chong-Kin Liam
    Yongfeng Yu
    Advances in Therapy, 2021, 38 : 2038 - 2053
  • [25] A combined analysis of two phase IIIb studies of afatinib in EGFR TKI-naive patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC
    de Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Egorova, I.
    Tan, E-H.
    Gottfried, M.
    Lee, V.
    Kowalski, D. M.
    Yang, C-T.
    Srinivasa, B. J.
    Passaro, A.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Zhou, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30 : 600 - 600
  • [26] Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
    Harvey, R. Donald
    Adams, Val R.
    Beardslee, Tyler
    Medina, Patrick
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (06) : 1461 - 1474
  • [27] Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC Treated with Daily Afatinib (Final Report)
    Yamamoto, N.
    Nukiwa, T.
    Nakanishi, Y.
    Gemma, A.
    Mizushima, M.
    Takayama, T.
    Kumazawa, J.
    Azuma, H.
    Tamura, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2213 - S2214
  • [28] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
    Liang, Sheng-Kai
    Hsieh, Min-Shu
    Lee, Meng-Rui
    Keng, Li-Ta
    Ko, Jen-Chung
    Shih, Jin-Yuan
    ONCOTARGET, 2017, 8 (52) : 90430 - 90443
  • [29] Real-world clinical experience of the Galician Lung Cancer Group: Afatinib in patients with EGFR positive mutation.
    Agraso Busto, Sara
    Varela, Vanesa
    Fernandez Nunez, Natalia
    Firvida, Jose-Luis
    Santome, Lucia
    Javier Afonso, Francisco
    Azpitarte, Cristina
    De Dios Alvarez, Noemi
    Garcia, Jorge
    Campos Balea, Begona
    Areses Manrique, Maria Carmen
    Pereiro Corbacho, Diego
    Huidobro, Gerardo
    Lazaro Quintela, Martin
    Casal Rubio, Joaquin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm plus ) NSCLC in LUX-Lung 3, 6 and 7
    Sequist, L. V.
    Wu, Y.
    Schuler, M.
    Kato, T.
    Yang, J. C.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Paz-Ares, L.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Tang, W.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1572 - S1572
12345